[Absorption of ceftizoxime from peritoneal dialysate and its pharmacokinetics in chronic kidney failure patients].
The pharmacokinetics of ceftizoxime (Cef) and its diffusivity across the peritoneal membrane were studied in 10 chronic kidney failure patients undergoing continuous ambulatory peritoneal dialysis. Cef was determined by HPLC. The results showed that the disposition of Cef could be described with a 2-compartment open model after 1 g intravenous infusion. VD = 20 +/- 5 L, AUC = 1237 +/- 327 micrograms.ml-1.h. T1/2 beta = 16.9 +/- 4.5 h, which was much longer than that of patients with normal renal function. Therefore, the regulation of dose regimen was necessary when treating patients with renal failure. Cef was partly eliminated by peritoneal dialysis with the ClD of 2.9 +/- 1.0 ml.min-1. The bidirectional exchange of Cef was seen between blood and dialysate. It is more suitable to describe the diffusive characteristics of Cef from dialysate (or blood) into blood (or dialysate) with a zero order constant rate model. The absorption percentage of Cef after 0.5 g instilled with peritoneal dialysate was 90.4 +/- 7.0%.
Gao
S
S
Department of Clinical Pharmacology, Changhai Hospital, Shanghai, China.
Li
P
P
Liu
G L
GL
Wang
S X
SX
Chui
R L
RL
Yang
J P
JP
D000042:Absorption; D015296:Ceftizoxime / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum
D015296:Ceftizoxime